87 related articles for article (PubMed ID: 6110951)
1. Enzyme-mediated resistance of Bacteroides fragilis to moxalactam.
Maskell JP; Nasu M
Lancet; 1981 Mar; 1(8222):733. PubMed ID: 6110951
[No Abstract] [Full Text] [Related]
2. Antibacteroides and beta-lactamase inhibitory activities of moxalactam.
Fu KP; Neu HC
J Antimicrob Chemother; 1981 Oct; 8(4):337-41. PubMed ID: 6271727
[No Abstract] [Full Text] [Related]
3. Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis.
Yotsuji A; Minami S; Kakizawa H; Yasuda T; Takai A; Saikawa I; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1985 Dec; 28(6):773-7. PubMed ID: 3878690
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
Brown JE; Del Bene VE; Collins CD
Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
[TBL] [Abstract][Full Text] [Related]
5. Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis.
Kesado T; Watanabe K; Asahi Y; Isono M; Ueno K
Antimicrob Agents Chemother; 1984 Jan; 25(1):131-3. PubMed ID: 6322676
[TBL] [Abstract][Full Text] [Related]
6. [In vitro and in vivo antimicrobial activities of cefmetazole against Bacteroides fragilis].
Isono M; Kawashima K; Yamada N; Aoki M; Kobayashi T; Sawa K; Watanabe K; Ueno K
Jpn J Antibiot; 1982 Jul; 35(7):1667-72. PubMed ID: 6757469
[TBL] [Abstract][Full Text] [Related]
7. [Timed bacteriostatic and bactericidal activities of latamoxef against clinical strains of gram-negative bacteria].
Masuda G; Negishi M; Young C; Mukaiyama T; Hanai N; Uchikawa S; Thoma T; Yamazaki E
Jpn J Antibiot; 1983 Jan; 36(1):16-21. PubMed ID: 6221128
[No Abstract] [Full Text] [Related]
8. [In vitro action of moxalactam on hospital bacteria. Results of a multicenter survey].
Duval J; Deforges L; Bergogne-Berezin E; Chabbert YA; Courtieu AL; Cluzel R; Dabernat H; Witchitz JL
Sem Hop; 1983 Jun; 59(26):1949-52. PubMed ID: 6310784
[TBL] [Abstract][Full Text] [Related]
9. [Moxalactam: preclinical evaluation].
Chabbert YA
Sem Hop; 1983 Jun; 59(26):1943-6. PubMed ID: 6310782
[No Abstract] [Full Text] [Related]
10. The activity of five cephalosporins against Bacteroides fragilis.
Ryan RW; Kwasnik I; Tilton RC
Ann Clin Lab Sci; 1982; 12(1):32-4. PubMed ID: 6279014
[No Abstract] [Full Text] [Related]
11. In-vitro and in-vivo activities of a novel cephamycin MT-141 against the Bacteroides fragilis group in comparison with six cephem antibiotics.
Kasai T; Hara T; Tamura A; Kazuno Y; Inouye S; Goto S; Kuwahara S
J Antimicrob Chemother; 1985 Jun; 15(6):701-14. PubMed ID: 3928575
[TBL] [Abstract][Full Text] [Related]
12. [Moxalactam: an inactivator of beta-lactamases].
Labia R
Sem Hop; 1983 Jun; 59(26):1959-62. PubMed ID: 6310786
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of the oxa-beta-lactam LY 127935 against Bacteroides fragilis and other anaerobic gram-negative rods (author's transl)].
Werner H; Krasemann C
Infection; 1980; 8 Suppl 3():S 342-6. PubMed ID: 6447673
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
[TBL] [Abstract][Full Text] [Related]
15. Beta-lactamases from Bacteroides fragilis active against oximino-cephalosporins.
Werner RG; Appel KR; Erne AM
Arzneimittelforschung; 1985; 35(1A):348-50. PubMed ID: 3872669
[TBL] [Abstract][Full Text] [Related]
16. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
[TBL] [Abstract][Full Text] [Related]
17. [In vitro evaluation of moxalactam on enterobacteria producing beta-lactamases].
Kazmierczak A; Pechinot A; Duez JM; Kohli E; Tremeaux JC
Sem Hop; 1983 Jun; 59(26):1953-7. PubMed ID: 6310785
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
[TBL] [Abstract][Full Text] [Related]
19. The in vitro responses of Bacteroides fragilis to Moxalactam, Cefotaxime, Cefmetazole, Josamycin and erythromycin.
Soriano F; Ponte MC; Gaspar MC
J Clin Pathol; 1982 Oct; 35(10):1166-7. PubMed ID: 6290543
[No Abstract] [Full Text] [Related]
20. Cephalosporin-resistance in the Bacteroides fragilis group and the effect of clavulanic acid.
Maskell JP; Nasu M; Williams JD
J Antimicrob Chemother; 1984 Jan; 13(1):23-30. PubMed ID: 6607916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
